Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combodart versus placebo for sexual function in sexually active men with benign prostatic hyperplasia
NL-OMON44013Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of alpha blocker + 5-alpha reductase inhibitor, dutasteride and tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by GSK. Primary endpoint: Change in total Men's Sexual Health Questionnaire score from baseline to month 12. Started Mar 2013; status: active, not recruiting.
02
Drugs
alpha blocker + 5-alpha reductase inhibitordutasteridetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NL-OMON44013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44013.